18:16 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Early data for Enyo's HBV, NASH candidate tee up Phase II

Enyo Pharma S.A. (Lyon, France) said once-daily oral EYP001 for four weeks was well tolerated with no off-target effects or serious adverse events reported in a Phase Ib trial to treat chronic HBV infection. The...
15:19 , May 4, 2018 |  BC Week In Review  |  Clinical News

Altimmune evaluating next steps for HBV vaccine

Altimmune Inc. (NASDAQ:ALT) said HepTcell (FP-02.2) given on days one, 29 and 57 as an add-on to entecavir or tenofovir was well tolerated but led to "inconclusive" T cell immunogenicity results in a Phase Ib...
22:21 , Oct 12, 2017 |  BC Innovations  |  Targets & Mechanisms

Mining the negatives

By investigating why its discontinued siRNA candidate against hepatitis B caused only weak responses in certain patients, Arrowhead Pharmaceuticals Inc. has upended a dogma about the virus’ genetics that has been clouding drug design and...
22:34 , Sep 28, 2017 |  BC Extra  |  Preclinical News

Arrowhead paper reveals additional HBV antigen source

A paper published in...
19:25 , Jul 31, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Cell models A high throughput cell co-culture system could be used to screen therapies for HBV infection. The system utilizes a microwell plate for simultaneously generating up to 96 co-cultures of pooled primary human...
21:22 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

ARC-520: Ph IIb hold

Arrowhead said FDA placed a clinical hold on the double-blind, placebo-controlled, U.S. Phase IIb Heparc-2004 trial of IV ARC-520. Arrowhead said FDA placed the hold after deaths occurred in a non-human primate toxicology study in...
23:22 , Nov 10, 2016 |  BC Week In Review  |  Clinical News

ABI-H0731: Ph I started

Assembly began a single-blind, placebo-controlled, New Zealand Phase I trial of oral ABI-H0731 in about 114 subjects. The first part will evaluate multiple doses of oral ABI-H0731 for 1, 7 or 28 days in healthy...
23:27 , Nov 9, 2016 |  BC Extra  |  Clinical News

Clinical hold for Arrowhead's HBV therapy

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) fell $1.91 (31%) to $4.20 on Wednesday after it said FDA placed a clinical hold on the Phase IIb Heparc-2004 trial of short interfering RNA therapy ARC-520 to treat HBV. The...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

ARC-520: Phase IIb started

Arrowhead began the open-label, Australian and New Zealand Phase IIb MONARCH (Heparc-2008) trial to evaluate 2 mg/kg IV ARC-520 every 4 weeks for 48 weeks alone or with entecavir and Pegasys peginterferon alfa-2a in up...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

ARC-520: Additional Phase IIa data

Top-line data from 6 treatment-naive hepatitis B e antigen (HBeAg)-positive patients with active chronic HBV infection in an open-label cohort of the double-blind, placebo-controlled, dose-escalation, Hong Kong Phase IIa Heparc-2001 trial showed that a single...